Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 1999

View Archived Issues

SmithKline Beecham: Annual Report 1998/Q1 Report 1999

Sepracor: Q1 1999 highlights

Positive results achieved in Alexion's phase I/II study of 5G1.1 in RA

Alcon to continue Lu-Tex development

Synthetic antitumor agent derived from Et 743 shows promise following preliminary testing

OraVax: Q4 and year-end 1998 highlights

Another series of HDL-increasing compounds revealed by American Home Products

FDA approves Roche's lipase inhibitor for marketing

Vertex and Glaxo Wellcome begin shipping new anti-HIV compound

Lorus to acquire GeneSense

New phenylpropionic acid derivatives with excellent antidiabetic effects

Vasodilating benzamide and cinnamide derivatives from China

China Pharmaceutical University develops effective antiarrhythmic agents

Genta and NCI to collaborate on G-3139 clinical development

Anti-CD11/CD18 MAb not effective in phase II trial in exacerbations of MS

Series from Takeda with neuroprotective effects

U.S. study now under way using artificial liver device incorporating human cells

RiboGene issued two patents related to translation-targeted drug discovery

Cellegy initiates phase II testing of Anogesic in hemorrhoid surgery patients

Urethra-selective alpha1-agonists under development at Mitsui for urinary incontinence

European CPMP emits positive opinion on Zeffix for chronic HBV

New cyclic compounds designed at JT reduce only elevated blood glucose levels

Amgen: Q1 1999 highlights

Dual-action antiatherosclerotic agents in the Sankyo pipeline

BRAINS results presented at American Academy of Neurology meeting

Therapeutic Antibodies: year-end 1998 highlights

Pregabalin: first clinical experience in patients with refractory complex partial seizures

Muscarinic agonists fail to improve cognitive function in AD

Noncompetitive AMPA antagonist potentiates levodopa activity in primate PD model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.